TY - JOUR
T1 - Measurement of free light chains with assays based on monoclonal antibodies
AU - Te Velthuis, Henk
AU - Drayson, Mark
AU - Campbell, John P
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite® (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.
AB - Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite® (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.
UR - http://dx.doi.org/10.1515/cclm-2015-0963
U2 - 10.1515/cclm-2015-0963
DO - 10.1515/cclm-2015-0963
M3 - Article
C2 - 27010775
SN - 1434-6621
VL - 54
SP - 1005
EP - 1014
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 6
ER -